

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
WF-1802	Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GU002	NRG GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8153	Cabaz with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED 2 Trial	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031102	GERM CELL TUMORS/Relapsed or Refractory; Male Only; Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment. Phase III Trial	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031501	Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

AREN03B2	COG-AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be <30 Years Old at the Time of Diagnosis	Biobanking	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1802	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) of The Primary Tumor in Metastatic Prostate Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031803	Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1806	Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031704	PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

NRG CC007CD	Increasing the Dose of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy	Cancer Care Delivery	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GU005	A Phase III IGRT + SBRT vs IGRT + Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8143	A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Merck 3475-641	A Phase III, Randomized, Double-blind, Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Merck MK 3475-921	A Phase III, Randomized, Double-blind, Study of Pembrolizumab (MK-3475) Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

AstraZeneca (PREVAIL)	A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression Using the Ventana SP263 Assay in the First-line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma	Other	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
AstraZeneca (NILE)	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer	Biorepository	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
